IN8bio Inc INAB shares are ripping higher Tuesday after a Form 4 filing with the SEC showed that Cavu Advisors has been buying shares of the clinical-stage biotech company. Positive analyst coverage from HC Wainwright & Co may also be adding to the move higher.
According to a recent regulatory filing, Cavu Advisors bought 51,214 shares of IN8bio over the last week at an average price of $2.02 per share.
HC Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on IN8bio with a Buy rating Tuesday and announced a price target of $14.
IN8bio focuses on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells.
See Also: Why Azure Power Global Stock Is Getting Obliterated Again Today
INAB Price Action: INAB has a 52-week high of $4.97 and a 52-week low of $1.75.
The stock was up 35.9% at $2.69 at press time, according to Benzinga Pro.
Photo: Konstantin Kolosov from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
